Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Opt Express ; 20(23): 25654-61, 2012 Nov 05.
Article in English | MEDLINE | ID: mdl-23187384

ABSTRACT

We report the measurement of the frequency noise power spectral density of a quantum cascade laser emitting at 2.5THz. The technique is based on heterodyning the laser emission frequency with a harmonic of the repetition rate of a near-infrared laser comb. This generates a beatnote in the radio frequency range that is demodulated using a tracking oscillator allowing measurement of the frequency noise. We find that the latter is strongly affected by the level of optical feedback, and obtain an intrinsic linewidth of ~230Hz, for an output power of 2mW.

2.
Health Phys ; 89(1): 92-4, 2005 Jul.
Article in English | MEDLINE | ID: mdl-15951696

ABSTRACT

KI and KIO3 are the commonly used prophylactic drugs for the protection of thyroid glands against radioiodine. In this study, we have demonstrated the use of another iodine containing salt, calcium iodate [Ca(IO3)2], as an effective blocker of radioiodine uptake by the thyroid gland in rats. Ca(IO3)2 is permitted by the FDA as a food additive and is "generally regarded as safe" (GRAS, CFR No.1206). We have also compared the efficacy of Ca(IO3)2 with KIO3 in blocking thyroidal uptake of radioiodine, which could be important considering the better shelf life of Ca(IO3)2. Laboratory rats were administered 131I and stable iodide in the form of KIO3 or Ca(IO3)2 was given orally, 2 h after the administration of 131I. All the animals were monitored for whole body retention (WBR) of 131I, at 24 h and further for 14 d. The results of the present study provide us with evidence that Ca(IO3)2 can serve as another promising radioiodine blocker, and is as equipotent as KI/KIO3 in protecting the thyroid gland. We have not found any studies that examined the property of Ca(IO3)2 in blocking radioiodine uptake by the thyroid gland and the present study is an attempt in this direction.


Subject(s)
Iodates/administration & dosage , Iodine Radioisotopes/analysis , Iodine Radioisotopes/pharmacokinetics , Radiation Injuries/prevention & control , Radiation Protection/methods , Radiation-Protective Agents/administration & dosage , Thyroid Gland/drug effects , Thyroid Gland/metabolism , Administration, Oral , Animals , Body Burden , Calcium/administration & dosage , Metabolic Clearance Rate/drug effects , Organ Specificity , Radiation Dosage , Radiation Tolerance/drug effects , Radiometry , Radiopharmaceuticals/analysis , Radiopharmaceuticals/pharmacokinetics , Rats , Rats, Wistar , Tissue Distribution/drug effects , Whole-Body Counting
3.
Health Phys ; 87(1): 46-50, 2004 Jul.
Article in English | MEDLINE | ID: mdl-15194921

ABSTRACT

Many trials based on the basic phenomena of isotopic dilution, adsorption, ion exchange, chelation, etc., have been attempted for the decorporation of radiostrontium, particularly Sr, after its entry in the in vivo system. We have recently demonstrated a non-isotopic carrier effect of some common calcium salts (calcium = 9 mg mL) to reduce the whole body retention of radiostrontium, if administered within 2 h after radiostrontium exposure and furthermore once daily, in rats, supplemented with calcium fortified diet. However, 25-30% of radiostrontium (compared to 50-60% in untreated animals) was still found to be retained in the animal even after 2 wk of treatment. Trial of some simple interventional measures, which would not adversely affect the animal metabolism, like pyrophosphate and magnesium sulfate, sodium citrate, chitin (a bio-absorbent), crown ether (a metal-chelator), and ammonium chloride, was therefore attempted to dislodge this remaining radiostrontium by switching over these animals to normal diet and subjecting them to different lines of treatment with these simple interventions through diet and drinking water separately for a further 4 wk. However, this remaining portion of radiostrontium is fixed in the bone and is difficult to dislodge.


Subject(s)
Bone and Bones/drug effects , Bone and Bones/metabolism , Calcium Compounds/administration & dosage , Calcium, Dietary/administration & dosage , Decontamination/methods , Radiation Protection/methods , Radiation-Protective Agents/administration & dosage , Strontium Radioisotopes/pharmacokinetics , Absorption , Administration, Oral , Adsorption , Animals , Antidotes/administration & dosage , Body Burden , Calcium Carbonate/administration & dosage , Calcium Compounds/pharmacokinetics , Calcium Gluconate/administration & dosage , Calcium Phosphates/administration & dosage , Calcium, Dietary/metabolism , Drug Administration Schedule , Injections, Intraperitoneal , Lactates/administration & dosage , Metabolic Clearance Rate/drug effects , Organ Specificity , Rats , Rats, Wistar , Strontium Radioisotopes/administration & dosage , Strontium Radioisotopes/toxicity , Tissue Distribution , Whole-Body Counting/methods
4.
J Radiol Prot ; 23(3): 317-26, 2003 Sep.
Article in English | MEDLINE | ID: mdl-14582722

ABSTRACT

In this study we have examined the effect of different calcium salts, Ca gluconate (CaG), Ca lactate (CaL), Ca carbonate (CaC) and Ca phosphate (CaP), on the clearance of radiostrontium (*Sr) administered either intraperitoneally (ip) (*Sr-ip group) or orally (*Sr-oral group) in rats. The influence of these Ca salts was examined in a group of animals administered *Sr ip, while the effect of three Ca salts (CaG, CaL and CaP) was studied in another group of rats given *Sr orally and compared with that of Ca alginate (CaA), normally advised for *Sr decorporation. Rats from both groups were subdivided into control and four experimental subgroups and were housed individually. The experimental subgroups were given the respective Ca salts (elemental Ca = 9 mg/rat/day) 2 h post 85Sr, and thereafter once daily. In the *Sr-ip group, CaG was administered ip while the other Ca salts were given orally. In the *Sr-oral group all Ca salts were administered orally. In addition, the diet of all the experimental subgroups was supplemented with the respective Ca salts to 2% elemental Ca. The whole-body retention (WBR) of *Sr in animals treated with Ca salts was found to be significantly reduced from 50-60% at 24 h to 20-30% at the end of 15 days compared with 70-80% at 24 h to 50-60% at the end of 15 days in the untreated control animals. The results strongly suggest that CaA could be replaced by any of the commonly used Ca salts for curtailing the WBR of *Sr. CaG which was administered ip, in the *Sr-ip group, was found to be more effective in reducing the WBR of *Sr.


Subject(s)
Body Burden , Calcium, Dietary/pharmacokinetics , Strontium Radioisotopes/metabolism , Administration, Oral , Animals , Antidotes/administration & dosage , Antidotes/pharmacokinetics , Calcium Carbonate/administration & dosage , Calcium Carbonate/pharmacokinetics , Calcium Compounds/administration & dosage , Calcium Compounds/pharmacokinetics , Calcium Gluconate/administration & dosage , Calcium Gluconate/pharmacokinetics , Calcium Phosphates/administration & dosage , Calcium Phosphates/pharmacokinetics , Calcium, Dietary/administration & dosage , Injections, Intraperitoneal , Lactates/administration & dosage , Lactates/pharmacokinetics , Rats , Rats, Wistar , Strontium Radioisotopes/toxicity , Time Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...